Sensus Healthcare, Inc.
Sensus Healthcare, Inc. (SRTS) Stock Competitors & Peer Comparison
See (SRTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRTS | $3.37 | -1.17% | 55.5M | -7.17 | -$0.47 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $84.35 | +2.17% | 146.9B | 23.63 | $3.57 | +2.88% |
| SYK | $294.45 | +4.20% | 112.8B | 34.04 | $8.65 | +1.17% |
| MDT | $76.82 | +3.06% | 98.7B | 21.47 | $3.58 | +3.70% |
| BSX | $54.10 | +1.37% | 80.5B | 22.65 | $2.39 | N/A |
| BRKRP | $346.31 | +2.58% | 52.7B | N/A | N/A | +0.45% |
| EW | $79.73 | +3.32% | 45.9B | 43.10 | $1.85 | N/A |
| PHG | $27.01 | +1.05% | 25.7B | 22.89 | $1.18 | +3.58% |
| DXCM | $61.14 | +3.05% | 23.6B | 26.24 | $2.33 | N/A |
Stock Comparison
SRTS vs BSX-PA Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SRTS is priced at $3.37, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SRTS's ROE is -0.16%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, SRTS is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BSX-PA's competition here
SRTS vs ABT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ABT has a market cap of 146.9B. Regarding current trading prices, SRTS is priced at $3.37, while ABT trades at $84.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ABT's P/E ratio is 23.63. In terms of profitability, SRTS's ROE is -0.16%, compared to ABT's ROE of +0.12%. Regarding short-term risk, SRTS is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ABT's competition here
SRTS vs SYK Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SYK has a market cap of 112.8B. Regarding current trading prices, SRTS is priced at $3.37, while SYK trades at $294.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SYK's P/E ratio is 34.04. In terms of profitability, SRTS's ROE is -0.16%, compared to SYK's ROE of +0.15%. Regarding short-term risk, SRTS is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SYK's competition here
SRTS vs MDT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, MDT has a market cap of 98.7B. Regarding current trading prices, SRTS is priced at $3.37, while MDT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas MDT's P/E ratio is 21.47. In terms of profitability, SRTS's ROE is -0.16%, compared to MDT's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check MDT's competition here
SRTS vs BSX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BSX has a market cap of 80.5B. Regarding current trading prices, SRTS is priced at $3.37, while BSX trades at $54.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BSX's P/E ratio is 22.65. In terms of profitability, SRTS's ROE is -0.16%, compared to BSX's ROE of +0.15%. Regarding short-term risk, SRTS is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BSX's competition here
SRTS vs BRKRP Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BRKRP has a market cap of 52.7B. Regarding current trading prices, SRTS is priced at $3.37, while BRKRP trades at $346.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BRKRP's P/E ratio is N/A. In terms of profitability, SRTS's ROE is -0.16%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, SRTS is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BRKRP's competition here
SRTS vs EW Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, EW has a market cap of 45.9B. Regarding current trading prices, SRTS is priced at $3.37, while EW trades at $79.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas EW's P/E ratio is 43.10. In terms of profitability, SRTS's ROE is -0.16%, compared to EW's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check EW's competition here
SRTS vs PHG Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, SRTS is priced at $3.37, while PHG trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PHG's P/E ratio is 22.89. In terms of profitability, SRTS's ROE is -0.16%, compared to PHG's ROE of +0.09%. Regarding short-term risk, SRTS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check PHG's competition here
SRTS vs DXCM Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, DXCM has a market cap of 23.6B. Regarding current trading prices, SRTS is priced at $3.37, while DXCM trades at $61.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas DXCM's P/E ratio is 26.24. In terms of profitability, SRTS's ROE is -0.16%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, SRTS is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check DXCM's competition here
SRTS vs STE Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, SRTS is priced at $3.37, while STE trades at $210.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas STE's P/E ratio is 29.41. In terms of profitability, SRTS's ROE is -0.16%, compared to STE's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check STE's competition here
SRTS vs ABMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SRTS is priced at $3.37, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SRTS's ROE is -0.16%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ABMD's competition here
SRTS vs ZBH Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ZBH has a market cap of 16.1B. Regarding current trading prices, SRTS is priced at $3.37, while ZBH trades at $83.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ZBH's P/E ratio is 21.61. In terms of profitability, SRTS's ROE is -0.16%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SRTS is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ZBH's competition here
SRTS vs SNN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, SRTS is priced at $3.37, while SNN trades at $30.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SNN's P/E ratio is 21.02. In terms of profitability, SRTS's ROE is -0.16%, compared to SNN's ROE of +0.12%. Regarding short-term risk, SRTS is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SNN's competition here
SRTS vs PEN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, SRTS is priced at $3.37, while PEN trades at $322.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PEN's P/E ratio is 74.23. In terms of profitability, SRTS's ROE is -0.16%, compared to PEN's ROE of +0.12%. Regarding short-term risk, SRTS is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check PEN's competition here
SRTS vs SWAV Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SRTS is priced at $3.37, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SRTS's ROE is -0.16%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SRTS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SWAV's competition here
SRTS vs ALGN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ALGN has a market cap of 11.9B. Regarding current trading prices, SRTS is priced at $3.37, while ALGN trades at $165.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ALGN's P/E ratio is 27.90. In terms of profitability, SRTS's ROE is -0.16%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ALGN's competition here
SRTS vs PODD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PODD has a market cap of 11B. Regarding current trading prices, SRTS is priced at $3.37, while PODD trades at $158.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PODD's P/E ratio is 37.02. In terms of profitability, SRTS's ROE is -0.16%, compared to PODD's ROE of +0.21%. Regarding short-term risk, SRTS is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check PODD's competition here
SRTS vs GMED Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, SRTS is priced at $3.37, while GMED trades at $76.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas GMED's P/E ratio is 17.79. In terms of profitability, SRTS's ROE is -0.16%, compared to GMED's ROE of +0.13%. Regarding short-term risk, SRTS is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check GMED's competition here
SRTS vs GKOS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, GKOS has a market cap of 8B. Regarding current trading prices, SRTS is priced at $3.37, while GKOS trades at $136.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas GKOS's P/E ratio is -41.34. In terms of profitability, SRTS's ROE is -0.16%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, SRTS is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check GKOS's competition here
SRTS vs BRKR Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BRKR has a market cap of 6.8B. Regarding current trading prices, SRTS is priced at $3.37, while BRKR trades at $44.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BRKR's P/E ratio is -186.37. In terms of profitability, SRTS's ROE is -0.16%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, SRTS is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BRKR's competition here
SRTS vs BIO-B Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BIO-B has a market cap of 6.6B. Regarding current trading prices, SRTS is priced at $3.37, while BIO-B trades at $245.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BIO-B's P/E ratio is 40.90. In terms of profitability, SRTS's ROE is -0.16%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, SRTS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BIO-B's competition here
SRTS vs BIO Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BIO has a market cap of 6.5B. Regarding current trading prices, SRTS is priced at $3.37, while BIO trades at $241.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BIO's P/E ratio is 40.31. In terms of profitability, SRTS's ROE is -0.16%, compared to BIO's ROE of +0.02%. Regarding short-term risk, SRTS is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BIO's competition here
SRTS vs NARI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SRTS is priced at $3.37, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, SRTS's ROE is -0.16%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SRTS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check NARI's competition here
SRTS vs LIVN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, SRTS is priced at $3.37, while LIVN trades at $71.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas LIVN's P/E ratio is 36.61. In terms of profitability, SRTS's ROE is -0.16%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, SRTS is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check LIVN's competition here
SRTS vs IRTC Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, SRTS is priced at $3.37, while IRTC trades at $118.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas IRTC's P/E ratio is -137.57. In terms of profitability, SRTS's ROE is -0.16%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, SRTS is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check IRTC's competition here
SRTS vs AXNX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SRTS is priced at $3.37, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SRTS's ROE is -0.16%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SRTS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AXNX's competition here
SRTS vs ITGR Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ITGR has a market cap of 2.9B. Regarding current trading prices, SRTS is priced at $3.37, while ITGR trades at $84.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ITGR's P/E ratio is 21.09. In terms of profitability, SRTS's ROE is -0.16%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, SRTS is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ITGR's competition here
SRTS vs TMDX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, TMDX has a market cap of 2.2B. Regarding current trading prices, SRTS is priced at $3.37, while TMDX trades at $63.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas TMDX's P/E ratio is 14.63. In terms of profitability, SRTS's ROE is -0.16%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, SRTS is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check TMDX's competition here
SRTS vs AXGN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, SRTS is priced at $3.37, while AXGN trades at $40.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AXGN's P/E ratio is -63.95. In terms of profitability, SRTS's ROE is -0.16%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, SRTS is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AXGN's competition here
SRTS vs NUVA Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SRTS is priced at $3.37, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SRTS's ROE is -0.16%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SRTS is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check NUVA's competition here
SRTS vs ESTA Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, SRTS is priced at $3.37, while ESTA trades at $69.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ESTA's P/E ratio is -47.06. In terms of profitability, SRTS's ROE is -0.16%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, SRTS is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check ESTA's competition here
SRTS vs UFPT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, SRTS is priced at $3.37, while UFPT trades at $220.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas UFPT's P/E ratio is 25.12. In terms of profitability, SRTS's ROE is -0.16%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, SRTS is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check UFPT's competition here
SRTS vs PRCT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, SRTS is priced at $3.37, while PRCT trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PRCT's P/E ratio is -15.70. In terms of profitability, SRTS's ROE is -0.16%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, SRTS is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check PRCT's competition here
SRTS vs AHCO Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, SRTS is priced at $3.37, while AHCO trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AHCO's P/E ratio is -19.07. In terms of profitability, SRTS's ROE is -0.16%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, SRTS is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AHCO's competition here
SRTS vs HSKA Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SRTS is priced at $3.37, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SRTS's ROE is -0.16%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SRTS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check HSKA's competition here
SRTS vs INSP Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, SRTS is priced at $3.37, while INSP trades at $44.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas INSP's P/E ratio is 10.02. In terms of profitability, SRTS's ROE is -0.16%, compared to INSP's ROE of +0.18%. Regarding short-term risk, SRTS is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check INSP's competition here
SRTS vs ATEC Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, SRTS is priced at $3.37, while ATEC trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ATEC's P/E ratio is -9.31. In terms of profitability, SRTS's ROE is -0.16%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, SRTS is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ATEC's competition here
SRTS vs AVNS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, SRTS is priced at $3.37, while AVNS trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AVNS's P/E ratio is -15.46. In terms of profitability, SRTS's ROE is -0.16%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, SRTS is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AVNS's competition here
SRTS vs AORT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while AORT trades at $23.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AORT's P/E ratio is 92.44. In terms of profitability, SRTS's ROE is -0.16%, compared to AORT's ROE of +0.03%. Regarding short-term risk, SRTS is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AORT's competition here
SRTS vs SILK Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, SRTS's ROE is -0.16%, compared to SILK's ROE of -0.35%. Regarding short-term risk, SRTS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SILK's competition here
SRTS vs FNA Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, SRTS's ROE is -0.16%, compared to FNA's ROE of -0.35%. Regarding short-term risk, SRTS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check FNA's competition here
SRTS vs BFLY Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while BFLY trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BFLY's P/E ratio is -13.88. In terms of profitability, SRTS's ROE is -0.16%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, SRTS is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BFLY's competition here
SRTS vs IRMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while IRMD trades at $84.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas IRMD's P/E ratio is 46.31. In terms of profitability, SRTS's ROE is -0.16%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, SRTS is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check IRMD's competition here
SRTS vs CNMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while CNMD trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CNMD's P/E ratio is 20.32. In terms of profitability, SRTS's ROE is -0.16%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, SRTS is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check CNMD's competition here
SRTS vs IART Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, SRTS is priced at $3.37, while IART trades at $13.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas IART's P/E ratio is -2.13. In terms of profitability, SRTS's ROE is -0.16%, compared to IART's ROE of -0.48%. Regarding short-term risk, SRTS is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check IART's competition here
SRTS vs LMRI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, SRTS is priced at $3.37, while LMRI trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas LMRI's P/E ratio is -15.91. In terms of profitability, SRTS's ROE is -0.16%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, SRTS is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check LMRI's competition here
SRTS vs TNDM Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, SRTS is priced at $3.37, while TNDM trades at $14.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas TNDM's P/E ratio is -10.72. In terms of profitability, SRTS's ROE is -0.16%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, SRTS is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check TNDM's competition here
SRTS vs INMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, INMD has a market cap of 876.3M. Regarding current trading prices, SRTS is priced at $3.37, while INMD trades at $13.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas INMD's P/E ratio is 10.24. In terms of profitability, SRTS's ROE is -0.16%, compared to INMD's ROE of +0.13%. Regarding short-term risk, SRTS is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check INMD's competition here
SRTS vs CSII Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SRTS is priced at $3.37, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, SRTS's ROE is -0.16%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SRTS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check CSII's competition here
SRTS vs SSII Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SSII has a market cap of 822.5M. Regarding current trading prices, SRTS is priced at $3.37, while SSII trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SSII's P/E ratio is -68.50. In terms of profitability, SRTS's ROE is -0.16%, compared to SSII's ROE of -0.30%. Regarding short-term risk, SRTS is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SSII's competition here
SRTS vs CRY Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, SRTS is priced at $3.37, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CRY's P/E ratio is 425.71. In terms of profitability, SRTS's ROE is -0.16%, compared to CRY's ROE of +0.03%. Regarding short-term risk, SRTS is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check CRY's competition here
SRTS vs BVS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BVS has a market cap of 685.9M. Regarding current trading prices, SRTS is priced at $3.37, while BVS trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BVS's P/E ratio is 24.73. In terms of profitability, SRTS's ROE is -0.16%, compared to BVS's ROE of +0.16%. Regarding short-term risk, SRTS is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BVS's competition here
SRTS vs BWAY Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BWAY has a market cap of 656.6M. Regarding current trading prices, SRTS is priced at $3.37, while BWAY trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BWAY's P/E ratio is 93.00. In terms of profitability, SRTS's ROE is -0.16%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check BWAY's competition here
SRTS vs CBLL Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CBLL has a market cap of 634.4M. Regarding current trading prices, SRTS is priced at $3.37, while CBLL trades at $16.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CBLL's P/E ratio is -11.47. In terms of profitability, SRTS's ROE is -0.16%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, SRTS is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check CBLL's competition here
SRTS vs SIBN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SIBN has a market cap of 615M. Regarding current trading prices, SRTS is priced at $3.37, while SIBN trades at $13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SIBN's P/E ratio is -31.59. In terms of profitability, SRTS's ROE is -0.16%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, SRTS is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check SIBN's competition here
SRTS vs SRDX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, SRTS is priced at $3.37, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, SRTS's ROE is -0.16%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, SRTS is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SRDX's competition here
SRTS vs APEN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SRTS is priced at $3.37, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, SRTS's ROE is -0.16%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SRTS is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check APEN's competition here
SRTS vs NPCE Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, NPCE has a market cap of 536.4M. Regarding current trading prices, SRTS is priced at $3.37, while NPCE trades at $15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas NPCE's P/E ratio is -23.94. In terms of profitability, SRTS's ROE is -0.16%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, SRTS is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check NPCE's competition here
SRTS vs ZIMV Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SRTS is priced at $3.37, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SRTS's ROE is -0.16%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, SRTS is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ZIMV's competition here
SRTS vs TCMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, TCMD has a market cap of 530.7M. Regarding current trading prices, SRTS is priced at $3.37, while TCMD trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas TCMD's P/E ratio is 27.05. In terms of profitability, SRTS's ROE is -0.16%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check TCMD's competition here
SRTS vs CTKB Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CTKB has a market cap of 521.7M. Regarding current trading prices, SRTS is priced at $3.37, while CTKB trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CTKB's P/E ratio is -6.97. In terms of profitability, SRTS's ROE is -0.16%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, SRTS is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check CTKB's competition here
SRTS vs CERS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CERS has a market cap of 510.9M. Regarding current trading prices, SRTS is priced at $3.37, while CERS trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CERS's P/E ratio is -51.00. In terms of profitability, SRTS's ROE is -0.16%, compared to CERS's ROE of -0.15%. Regarding short-term risk, SRTS is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check CERS's competition here
SRTS vs OFIX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, OFIX has a market cap of 492.3M. Regarding current trading prices, SRTS is priced at $3.37, while OFIX trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas OFIX's P/E ratio is -8.12. In terms of profitability, SRTS's ROE is -0.16%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, SRTS is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check OFIX's competition here
SRTS vs KIDS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, KIDS has a market cap of 455.1M. Regarding current trading prices, SRTS is priced at $3.37, while KIDS trades at $17.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas KIDS's P/E ratio is -10.55. In terms of profitability, SRTS's ROE is -0.16%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, SRTS is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check KIDS's competition here
SRTS vs VREX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, VREX has a market cap of 415.5M. Regarding current trading prices, SRTS is priced at $3.37, while VREX trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas VREX's P/E ratio is -4.93. In terms of profitability, SRTS's ROE is -0.16%, compared to VREX's ROE of -0.18%. Regarding short-term risk, SRTS is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check VREX's competition here
SRTS vs LAB Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, LAB has a market cap of 394.3M. Regarding current trading prices, SRTS is priced at $3.37, while LAB trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas LAB's P/E ratio is -7.77. In terms of profitability, SRTS's ROE is -0.16%, compared to LAB's ROE of +0.17%. Regarding short-term risk, SRTS is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check LAB's competition here
SRTS vs DCTH Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, DCTH has a market cap of 391.5M. Regarding current trading prices, SRTS is priced at $3.37, while DCTH trades at $11.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas DCTH's P/E ratio is 1134.00. In terms of profitability, SRTS's ROE is -0.16%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, SRTS is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check DCTH's competition here
SRTS vs PACB Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PACB has a market cap of 386.6M. Regarding current trading prices, SRTS is priced at $3.37, while PACB trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PACB's P/E ratio is -0.70. In terms of profitability, SRTS's ROE is -0.16%, compared to PACB's ROE of -4.88%. Regarding short-term risk, SRTS is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check PACB's competition here
SRTS vs CLPT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CLPT has a market cap of 379M. Regarding current trading prices, SRTS is priced at $3.37, while CLPT trades at $12.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CLPT's P/E ratio is -14.04. In terms of profitability, SRTS's ROE is -0.16%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, SRTS is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check CLPT's competition here
SRTS vs VMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, VMD has a market cap of 358.8M. Regarding current trading prices, SRTS is priced at $3.37, while VMD trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas VMD's P/E ratio is 25.30. In terms of profitability, SRTS's ROE is -0.16%, compared to VMD's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check VMD's competition here
SRTS vs SMLR Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SRTS is priced at $3.37, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SRTS's ROE is -0.16%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, SRTS is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SMLR's competition here
SRTS vs CATX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CATX has a market cap of 293.6M. Regarding current trading prices, SRTS is priced at $3.37, while CATX trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CATX's P/E ratio is -2.70. In terms of profitability, SRTS's ROE is -0.16%, compared to CATX's ROE of -0.42%. Regarding short-term risk, SRTS is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check CATX's competition here
SRTS vs MASS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, MASS has a market cap of 289.3M. Regarding current trading prices, SRTS is priced at $3.37, while MASS trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas MASS's P/E ratio is -7.89. In terms of profitability, SRTS's ROE is -0.16%, compared to MASS's ROE of -0.26%. Regarding short-term risk, SRTS is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check MASS's competition here
SRTS vs PMI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PMI has a market cap of 281M. Regarding current trading prices, SRTS is priced at $3.37, while PMI trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PMI's P/E ratio is -0.24. In terms of profitability, SRTS's ROE is -0.16%, compared to PMI's ROE of +2.17%. Regarding short-term risk, SRTS is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check PMI's competition here
SRTS vs SGHT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SGHT has a market cap of 268.2M. Regarding current trading prices, SRTS is priced at $3.37, while SGHT trades at $4.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SGHT's P/E ratio is -7.04. In terms of profitability, SRTS's ROE is -0.16%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, SRTS is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check SGHT's competition here
SRTS vs AVR Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, AVR has a market cap of 246.5M. Regarding current trading prices, SRTS is priced at $3.37, while AVR trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas AVR's P/E ratio is -2.63. In terms of profitability, SRTS's ROE is -0.16%, compared to AVR's ROE of -5.28%. Regarding short-term risk, SRTS is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check AVR's competition here
SRTS vs MGRM Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SRTS is priced at $3.37, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas MGRM's P/E ratio is -11.11. In terms of profitability, SRTS's ROE is -0.16%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, SRTS is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check MGRM's competition here
SRTS vs SENS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SENS has a market cap of 240.7M. Regarding current trading prices, SRTS is priced at $3.37, while SENS trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SENS's P/E ratio is -2.92. In terms of profitability, SRTS's ROE is -0.16%, compared to SENS's ROE of -1.31%. Regarding short-term risk, SRTS is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check SENS's competition here
SRTS vs RXST Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, RXST has a market cap of 228.5M. Regarding current trading prices, SRTS is priced at $3.37, while RXST trades at $5.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas RXST's P/E ratio is -4.88. In terms of profitability, SRTS's ROE is -0.16%, compared to RXST's ROE of -0.17%. Regarding short-term risk, SRTS is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check RXST's competition here
SRTS vs ELMD Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ELMD has a market cap of 226.7M. Regarding current trading prices, SRTS is priced at $3.37, while ELMD trades at $27.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ELMD's P/E ratio is 26.59. In terms of profitability, SRTS's ROE is -0.16%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, SRTS is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ELMD's competition here
SRTS vs NVRO Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SRTS is priced at $3.37, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SRTS's ROE is -0.16%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SRTS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check NVRO's competition here
SRTS vs PROF Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, PROF has a market cap of 216.1M. Regarding current trading prices, SRTS is priced at $3.37, while PROF trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas PROF's P/E ratio is -5.76. In terms of profitability, SRTS's ROE is -0.16%, compared to PROF's ROE of -0.45%. Regarding short-term risk, SRTS is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check PROF's competition here
SRTS vs EYES Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, SRTS is priced at $3.37, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas EYES's P/E ratio is N/A. In terms of profitability, SRTS's ROE is -0.16%, compared to EYES's ROE of -3.17%. Regarding short-term risk, SRTS is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check EYES's competition here
SRTS vs QTI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, QTI has a market cap of 200.9M. Regarding current trading prices, SRTS is priced at $3.37, while QTI trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas QTI's P/E ratio is -3.68. In terms of profitability, SRTS's ROE is -0.16%, compared to QTI's ROE of +3.64%. Regarding short-term risk, SRTS is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check QTI's competition here
SRTS vs ANIK Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, ANIK has a market cap of 195.2M. Regarding current trading prices, SRTS is priced at $3.37, while ANIK trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas ANIK's P/E ratio is -18.57. In terms of profitability, SRTS's ROE is -0.16%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, SRTS is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check ANIK's competition here
SRTS vs BSGM Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SRTS is priced at $3.37, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SRTS's ROE is -0.16%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, SRTS is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check BSGM's competition here
SRTS vs INGN Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, INGN has a market cap of 182.5M. Regarding current trading prices, SRTS is priced at $3.37, while INGN trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas INGN's P/E ratio is -7.34. In terms of profitability, SRTS's ROE is -0.16%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SRTS is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check INGN's competition here
SRTS vs MDGS Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SRTS is priced at $3.37, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SRTS's ROE is -0.16%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SRTS is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check MDGS's competition here
SRTS vs TLSI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, TLSI has a market cap of 172.9M. Regarding current trading prices, SRTS is priced at $3.37, while TLSI trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas TLSI's P/E ratio is -2.48. In terms of profitability, SRTS's ROE is -0.16%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, SRTS is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check TLSI's competition here
SRTS vs APYX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, APYX has a market cap of 170.8M. Regarding current trading prices, SRTS is priced at $3.37, while APYX trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas APYX's P/E ratio is -18.55. In terms of profitability, SRTS's ROE is -0.16%, compared to APYX's ROE of -0.91%. Regarding short-term risk, SRTS is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check APYX's competition here
SRTS vs QIPT Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, SRTS is priced at $3.37, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, SRTS's ROE is -0.16%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SRTS is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check QIPT's competition here
SRTS vs EDAP Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, EDAP has a market cap of 152.9M. Regarding current trading prices, SRTS is priced at $3.37, while EDAP trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas EDAP's P/E ratio is -4.98. In terms of profitability, SRTS's ROE is -0.16%, compared to EDAP's ROE of -1.56%. Regarding short-term risk, SRTS is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check EDAP's competition here
SRTS vs TMCI Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, TMCI has a market cap of 148.7M. Regarding current trading prices, SRTS is priced at $3.37, while TMCI trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas TMCI's P/E ratio is -2.39. In terms of profitability, SRTS's ROE is -0.16%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, SRTS is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check TMCI's competition here
SRTS vs HYPR Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, HYPR has a market cap of 141.3M. Regarding current trading prices, SRTS is priced at $3.37, while HYPR trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas HYPR's P/E ratio is -4.02. In terms of profitability, SRTS's ROE is -0.16%, compared to HYPR's ROE of -0.97%. Regarding short-term risk, SRTS is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check HYPR's competition here
SRTS vs CVRX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, CVRX has a market cap of 138.7M. Regarding current trading prices, SRTS is priced at $3.37, while CVRX trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas CVRX's P/E ratio is -2.58. In terms of profitability, SRTS's ROE is -0.16%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, SRTS is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check CVRX's competition here
SRTS vs SNWV Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, SNWV has a market cap of 137.9M. Regarding current trading prices, SRTS is priced at $3.37, while SNWV trades at $16.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas SNWV's P/E ratio is 39.12. In terms of profitability, SRTS's ROE is -0.16%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, SRTS is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check SNWV's competition here
SRTS vs QTRX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, QTRX has a market cap of 137.1M. Regarding current trading prices, SRTS is priced at $3.37, while QTRX trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas QTRX's P/E ratio is -1.24. In terms of profitability, SRTS's ROE is -0.16%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, SRTS is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check QTRX's competition here
SRTS vs NNOX Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, NNOX has a market cap of 119M. Regarding current trading prices, SRTS is priced at $3.37, while NNOX trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas NNOX's P/E ratio is -1.47. In terms of profitability, SRTS's ROE is -0.16%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, SRTS is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.Check NNOX's competition here
SRTS vs RPID Comparison May 2026
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 55.5M. In comparison, RPID has a market cap of 118.1M. Regarding current trading prices, SRTS is priced at $3.37, while RPID trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of -7.17, whereas RPID's P/E ratio is -2.58. In terms of profitability, SRTS's ROE is -0.16%, compared to RPID's ROE of -0.95%. Regarding short-term risk, SRTS is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.Check RPID's competition here